Agreement covers Medidata’s broad range of solutions to improve clinical trial efficiency
NEW YORK–(ANTARA/Business Wire)–Medidata, a Dassault Systèmes company and a leading provider of clinical trial solutions to the life sciences industry, today announced the renewal of its partnership with Thermo Fisher Scientific Inc.’s PPD clinical research business.
The agreement includes the Medidata Platform, Medidata Adjudicate and other Medidata Rave products to support PPD’s clinical research business in advancing customers’ drug development programs.
A key element of this relationship is the development of PPD TrueCast, a commercial solution powered by Medidata AI that reduces study time by combining patient recruitment and site performance data to deliver powerful predictive models and advanced analytics.
“Over the past 15 years, we have developed valuable relationships with PPD’s clinical research business to improve visibility and decision-making during clinical trials,” said Janet Butler, executive vice president and global head of sales at Medidata. “We look forward to working together to Complete research faster, improve drug development efficiency, and ultimately bring life-changing treatments to patients faster.”
Medidata has partnered with PPD’s clinical research business since 2009 to conduct more than 1,000 clinical studies for biopharmaceutical and medical device companies across a broad range of therapeutic areas from oncology to vaccines.
About McGrady Data
Medidata supports clinical trials with digital solutions that support smarter treatments and healthier people. Medidata celebrates 25 years of groundbreaking technology innovation across more than 32,000 trials and 9 million patients, delivering industry-leading expertise, analytics-driven insights and the world’s largest patient-level historical clinical trial data set. More than 1 million registered users across more than 2,200 customers trust Medidata’s seamless end-to-end platform to improve the patient experience, accelerate clinical breakthroughs and bring therapies to market faster. Medidata, a Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA) company, is headquartered in New York City and is recognized as a Leader by the Everest Group and IDC. For more information, visit www.medidata.com and follow us @Medidata.
About Dassault Systèmes
Dassault Systèmes, a 3DEXPERIENCE® company, is a catalyst for human progress. We provide collaborative virtual environments for businesses and people to imagine sustainable innovation. By using our 3DEXPERIENCE platform and applications to create virtual twin experiences of the real world, our customers can redefine the creation, production and lifecycle management processes of their products to create a meaningful impact and make the world more sustainable. The beauty of the experience economy is that it is a people-centered economy that benefits all consumers, patients, and citizens. Dassault Systèmes brings value to more than 300,000 customers of all sizes in more than 150 countries and industries. For more information, please visit www.3ds.com.
© Dassault Systèmes. all rights reserved. 3DEXPERIENCE, 3DS logo, compass icon, IFWE, 3DEXCITE, 3DVIA, BIOVIA, CATIA, CENTRIC PLM, DELMIA, ENOVIA, GEOVIA, MEDIDATA, NETVIBES, OUTSCALE, SIMULIA and SOLIDWORKS are trade marks or trade marks of Dassaults SystSomes Europe. ) is incorporated under the laws of France and registered in the Register of Trade and Companies of Versailles under number 322 306 440, or its subsidiaries in the United States and/or other countries.
contact method
Medical Data PR
Analyst Relations
Source: Medidata
